These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 30129214)

  • 1. Secukinumab-induced paradoxical pustular psoriasis.
    Dogra S; Bishnoi A; Narang T; Handa S
    Clin Exp Dermatol; 2019 Jan; 44(1):72-73. PubMed ID: 30129214
    [No Abstract]   [Full Text] [Related]  

  • 2. Acute Generalized Pustular Psoriasis Treated With the IL-17A Antibody Secukinumab.
    Böhner A; Roenneberg S; Eyerich K; Eberlein B; Biedermann T
    JAMA Dermatol; 2016 Apr; 152(4):482-4. PubMed ID: 26650014
    [No Abstract]   [Full Text] [Related]  

  • 3. Risankizumab-induced paradoxical pustular psoriasis.
    McFeely O; Pender E; Victory L; Almutlaq H; Storan E
    Clin Exp Dermatol; 2022 Mar; 47(3):616-617. PubMed ID: 34748673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secukinumab: a review in moderate to severe plaque psoriasis.
    Garnock-Jones KP
    Am J Clin Dermatol; 2015 Aug; 16(4):323-330. PubMed ID: 26202871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recalcitrant, generalized pustular psoriasis: rapid and lasting therapeutic response to antitumour necrosis factor-alpha antibody (infliximab).
    Schmick K; Grabbe J
    Br J Dermatol; 2004 Feb; 150(2):367. PubMed ID: 14996114
    [No Abstract]   [Full Text] [Related]  

  • 6. Anti IL-17 flared psoriasis in a patient on secukinumab.
    Noell C; McQuade B; Gottlieb A; Rosmarin D
    Dermatol Ther; 2017 Jul; 30(4):. PubMed ID: 28547879
    [No Abstract]   [Full Text] [Related]  

  • 7. Review of treatments for generalized pustular psoriasis.
    Kearns DG; Chat VS; Zang PD; Han G; Wu JJ
    J Dermatolog Treat; 2021 Aug; 32(5):492-494. PubMed ID: 31697211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of refractory juvenile generalized pustular psoriasis with secukinumab monotherapy: A case report and review of published work.
    Ho PH; Tsai TF
    J Dermatol; 2018 Nov; 45(11):1353-1356. PubMed ID: 30230584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE).
    Paul C; Lacour JP; Tedremets L; Kreutzer K; Jazayeri S; Adams S; Guindon C; You R; Papavassilis C;
    J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1082-90. PubMed ID: 25243910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of tumor necrosis factor-α, interleukin-23 and interleukin-17A inhibitors on bodyweight and body mass index in patients with psoriasis.
    Takamura S; Takahashi A; Inoue Y; Teraki Y
    J Dermatol; 2018 Sep; 45(9):1130-1134. PubMed ID: 30004583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secukinumab (AIN-457) for the treatment of Psoriasis.
    Jaleel T; Elmets C; Weinkle A; Kassira S; Elewski B
    Expert Rev Clin Pharmacol; 2016; 9(2):187-202. PubMed ID: 26647300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis.
    AbuHilal M; Walsh S; Shear N
    J Cutan Med Surg; 2016 Nov; 20(6):509-516. PubMed ID: 27207350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of secukinumab in the treatment of psoriasis.
    Blauvelt A
    Expert Opin Drug Saf; 2016 Oct; 15(10):1413-20. PubMed ID: 27545070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study.
    Imafuku S; Honma M; Okubo Y; Komine M; Ohtsuki M; Morita A; Seko N; Kawashima N; Ito S; Shima T; Nakagawa H
    J Dermatol; 2016 Sep; 43(9):1011-7. PubMed ID: 26919410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generalized pustular psoriasis complicated with idiopathic retroperitoneal fibrosis successfully treated with infliximab.
    Ito M; Akutsu K; Isobe M; Okazaki S; Ichiyama S; Hoashi T; Kanda N; Saeki H
    J Dermatol; 2021 Sep; 48(9):e436-e437. PubMed ID: 34080221
    [No Abstract]   [Full Text] [Related]  

  • 16. Broadalumab (Siliq)--another IL-17A antagonist for psoriasis.
    Med Lett Drugs Ther; 2017 Jul; 59(1525):118-119. PubMed ID: 28699932
    [No Abstract]   [Full Text] [Related]  

  • 17. Tildrakizumab (Ilumya) - another IL-23 antagonist for psoriasis.
    Med Lett Drugs Ther; 2019 Jan; 60(1563):4-6. PubMed ID: 30681661
    [No Abstract]   [Full Text] [Related]  

  • 18. [Blasch-kolinear psoriasis revealed by infliximab therapy].
    Sfia M; Roth-Mall B; Tortel MC; Guillaume JC; Cribier B
    Ann Dermatol Venereol; 2009 Dec; 136(12):898-903. PubMed ID: 20004317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept.
    Strober B; Gottlieb AB; Sherif B; Mollon P; Gilloteau I; McLeod L; Fox T; Mordin M; Gnanasakthy A; Papavassilis C; Lebwohl MG
    J Am Acad Dermatol; 2017 Apr; 76(4):655-661. PubMed ID: 28087133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment of recalcitrant palmoplantar pustular psoriasis with sequential use of infliximab and adalimumab.
    Yawalkar N; Hunger RE
    Dermatology; 2009; 218(1):79-83. PubMed ID: 18974629
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.